Effect of ASP8062 on morphine self-administration and morphine-induced respiratory suppression in monkeys
ASP8062 is an orally available GABAB receptor positive allosteric modulator (PAM). This study assessed the potential of ASP8062 for treating opioid use disorder (OUD). Three rhesus monkeys were pretreated with ASP8062 (0.3, 1 or 3 mg/kg) by oral administration 1 h prior to a 2-h morphine self-admini...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-04-01
|
| Series: | Journal of Pharmacological Sciences |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1347861323000087 |
| _version_ | 1797869872809508864 |
|---|---|
| author | Shinobu Akuzawa Megumi Irie Masayuki Kanki Takafumi Shirakawa Yuichiro Sato |
| author_facet | Shinobu Akuzawa Megumi Irie Masayuki Kanki Takafumi Shirakawa Yuichiro Sato |
| author_sort | Shinobu Akuzawa |
| collection | DOAJ |
| description | ASP8062 is an orally available GABAB receptor positive allosteric modulator (PAM). This study assessed the potential of ASP8062 for treating opioid use disorder (OUD). Three rhesus monkeys were pretreated with ASP8062 (0.3, 1 or 3 mg/kg) by oral administration 1 h prior to a 2-h morphine self-administration session (0.03 mg/kg, iv, per injection) under a fixed-ratio 5 schedule. We further examined the potential worsening of morphine-induced respiratory suppression by ASP8062 after coadministration of morphine (10 mg/kg, sc) and ASP8062 (10 mg/kg, po) in cynomolgus monkeys using a custom-made whole-body plethysmograph. Plasma concentrations of ASP8062 (3 or 10 mg/kg, po) were assessed in cynomolgus monkeys using liquid chromatography-tandem mass spectroscopy (LC-MS/MS). ASP8062 at 3 mg/kg, po decreased the morphine self-administrations with significant differences from the vehicle-treated group (IC50 = 0.97 ± 0.36 mg/kg). Exposure levels at 3 mg/kg observed in monkeys were comparable to the clinical exposure levels which positive pharmacodynamic effects were previously shown. Further, ASP8062 did not potentiate morphine-induced respiratory suppression up to exposure levels higher than the clinically relevant dose. ASP8062 may reduce opioid use in OUD patients without affecting respiratory system, providing justification for further ASP8062 development as a potential treatment option for OUD. |
| first_indexed | 2024-04-10T00:18:17Z |
| format | Article |
| id | doaj.art-ed09f3019ecf440cb4dd646207ab770d |
| institution | Directory Open Access Journal |
| issn | 1347-8613 |
| language | English |
| last_indexed | 2024-04-10T00:18:17Z |
| publishDate | 2023-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Pharmacological Sciences |
| spelling | doaj.art-ed09f3019ecf440cb4dd646207ab770d2023-03-16T05:03:14ZengElsevierJournal of Pharmacological Sciences1347-86132023-04-011514171176Effect of ASP8062 on morphine self-administration and morphine-induced respiratory suppression in monkeysShinobu Akuzawa0Megumi Irie1Masayuki Kanki2Takafumi Shirakawa3Yuichiro Sato4Applied Pharmacology, Non-clinical Regulatory Science, Applied Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, 305-8585, Japan; Corresponding author.Applied Drug Metabolism & Pharmacokinetics, Non-clinical Regulatory Science, Applied Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, 305-8585, JapanApplied Safety, Non-clinical Regulatory Science, Applied Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, 305-8585, JapanApplied Safety, Non-clinical Regulatory Science, Applied Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, 305-8585, JapanResearch Program Management, Applied Research Management, Applied Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, 305-8585, JapanASP8062 is an orally available GABAB receptor positive allosteric modulator (PAM). This study assessed the potential of ASP8062 for treating opioid use disorder (OUD). Three rhesus monkeys were pretreated with ASP8062 (0.3, 1 or 3 mg/kg) by oral administration 1 h prior to a 2-h morphine self-administration session (0.03 mg/kg, iv, per injection) under a fixed-ratio 5 schedule. We further examined the potential worsening of morphine-induced respiratory suppression by ASP8062 after coadministration of morphine (10 mg/kg, sc) and ASP8062 (10 mg/kg, po) in cynomolgus monkeys using a custom-made whole-body plethysmograph. Plasma concentrations of ASP8062 (3 or 10 mg/kg, po) were assessed in cynomolgus monkeys using liquid chromatography-tandem mass spectroscopy (LC-MS/MS). ASP8062 at 3 mg/kg, po decreased the morphine self-administrations with significant differences from the vehicle-treated group (IC50 = 0.97 ± 0.36 mg/kg). Exposure levels at 3 mg/kg observed in monkeys were comparable to the clinical exposure levels which positive pharmacodynamic effects were previously shown. Further, ASP8062 did not potentiate morphine-induced respiratory suppression up to exposure levels higher than the clinically relevant dose. ASP8062 may reduce opioid use in OUD patients without affecting respiratory system, providing justification for further ASP8062 development as a potential treatment option for OUD.http://www.sciencedirect.com/science/article/pii/S1347861323000087GABAB receptor Positive allosteric modulatorSelf-administrationRhesus monkeyCynomolgus monkeyOpioid use disorder |
| spellingShingle | Shinobu Akuzawa Megumi Irie Masayuki Kanki Takafumi Shirakawa Yuichiro Sato Effect of ASP8062 on morphine self-administration and morphine-induced respiratory suppression in monkeys Journal of Pharmacological Sciences GABAB receptor Positive allosteric modulator Self-administration Rhesus monkey Cynomolgus monkey Opioid use disorder |
| title | Effect of ASP8062 on morphine self-administration and morphine-induced respiratory suppression in monkeys |
| title_full | Effect of ASP8062 on morphine self-administration and morphine-induced respiratory suppression in monkeys |
| title_fullStr | Effect of ASP8062 on morphine self-administration and morphine-induced respiratory suppression in monkeys |
| title_full_unstemmed | Effect of ASP8062 on morphine self-administration and morphine-induced respiratory suppression in monkeys |
| title_short | Effect of ASP8062 on morphine self-administration and morphine-induced respiratory suppression in monkeys |
| title_sort | effect of asp8062 on morphine self administration and morphine induced respiratory suppression in monkeys |
| topic | GABAB receptor Positive allosteric modulator Self-administration Rhesus monkey Cynomolgus monkey Opioid use disorder |
| url | http://www.sciencedirect.com/science/article/pii/S1347861323000087 |
| work_keys_str_mv | AT shinobuakuzawa effectofasp8062onmorphineselfadministrationandmorphineinducedrespiratorysuppressioninmonkeys AT megumiirie effectofasp8062onmorphineselfadministrationandmorphineinducedrespiratorysuppressioninmonkeys AT masayukikanki effectofasp8062onmorphineselfadministrationandmorphineinducedrespiratorysuppressioninmonkeys AT takafumishirakawa effectofasp8062onmorphineselfadministrationandmorphineinducedrespiratorysuppressioninmonkeys AT yuichirosato effectofasp8062onmorphineselfadministrationandmorphineinducedrespiratorysuppressioninmonkeys |